PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK
Pfizer Inc. (NYSE: PFE) reported solid financial results for third-quarter 2022 and updated certain components of 2022 financial guidance (4). Pfizer raised the lower end of its 2022 revenue guidance range, while raising and narrowing its Adjusted diluted EPS (3) guidance, despite unfavorable impacts from foreign exchange. Revenue guidance for Comirnaty (1) was raised by $2 billion, and was reaffirmed for Paxlovid
By AP News
Published - Nov 01, 2022, 06:48 AM ET
Last Updated - Mar 15, 2024, 12:28 PM EDT
NEW YORK--(BUSINESS WIRE)--Nov 1, 2022--
Pfizer Inc. (NYSE: PFE) reported solid financial results for third-quarter 2022 and updated certain components of 2022 financial guidance (4). Pfizer raised the lower end of its 2022 revenue guidance range, while raising and narrowing its Adjusted diluted EPS (3) guidance, despite unfavorable impacts from foreign exchange. Revenue guidance for Comirnaty (1) was raised by $2 billion, and was reaffirmed for Paxlovid.
The third-quarter 2022 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.
EXECUTIVE COMMENTARY
